Apeloa Pharmaceutical's (SHE:000739) unit, Zhejiang Apeloa Jiayuan Pharmaceutical, received approval from China's National Medical Products Administration for the marketing of an active pharmaceutical ingredient for Fulzerasib, according to a Thursday.
The drug is used for the treatment of adults with advanced KRAS G12C-mutant non-small cell lung cancer.
The Chinese pharmaceutical company's shares fell 2% during the afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.